Skip to main content
. 2021 Jul;10(7):3106–3119. doi: 10.21037/tlcr-21-52

Figure 4.

Figure 4

Forest plots for efficacy endpoints indirect comparisons among combination regimens (single IO agent, IO + CT, Combo IO) for PD-L1 agents according to PD-L1 expression: PD-L1 ≥50% (A); PD-L1 <1% (B). No data available for PD-L1 1–49% subgroup. IO, single-agent immunotherapy; IO + CT, immunotherapy plus standard platinum-based doublet; Combo IO, immunotherapy combination regimens; ORR, overall response rate; PFS, progression-free survival; OS, overall survival.